COMMUNIQUÉS West-GlobeNewswire

SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments
11/02/2026
February 11, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the research consortium is coordinated by Philips, together with Erasmus MC as academic lead, and will combine advanced medical imaging and [...]
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
11/02/2026
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational treatment Madrigal [...]
HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
11/02/2026
Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib [...]
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
11/02/2026
Lugano, Switzerland – February 11th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and MagnaPharm, a leading pharmaceutical [...]
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
11/02/2026
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically [...]
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
11/02/2026
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization [...]
AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences
11/02/2026
DUBLIN and BERWYN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces expanded leadership roles [...]
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
11/02/2026
-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. [...]
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
11/02/2026
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally supported [...]
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
11/02/2026
BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will [...]
Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota
11/02/2026
The appointment of former General Manager of Novo Nordisk UK follows the recent appointment of Professor Sir Jonathan Van-Tam to Reset Health’s Advisory Board LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the [...]
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
11/02/2026
Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy product Partnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 [...]
InfiniHealth Medical Group Announces Integrated Multispecialty Care Model to Support Coordinated Specialty Services Across New Jersey
11/02/2026
WEST ORANGE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- InfiniHealth Medical Group today announced the continued advancement of its integrated multispecialty care model, a clinical framework that brings multiple board- [...]
Galecto Announces Pricing of $275 Million Underwritten Public Offering
11/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
11/02/2026
TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
Berlin Protocol Performance Enhancer Product Information Updated — What Do Consumers Consider When Researching Male Enhancement Supplement Options in 2026?
11/02/2026
An informational overview examining what consumers research about Berlin Protocol Performance Enhancer, ingredient transparency in the male enhancement supplement category, and what publicly available product [...]
Galapagos Receives Transparency Notifications from Bank of America
10/02/2026
Mechelen, Belgium ; February 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation [...]
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
10/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
10/02/2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]

Pages